You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
賽生藥業(06600.HK)2023年純利增加約31.2%至11.2億元
格隆匯 03-28 12:05

格隆匯3月28日丨 賽生藥業(06600.HK)公吿,截至2023年12月31日止年度,收入約為人民幣31.56億百萬元,增長約為14.8%,自2017年集團重組以來複合年增長率實現雙位數增長;純利增加約31.2%至人民幣11.2億元。剔除一次性公允價值變動及減值虧損後,核心純利約為人民幣12.37億元,較截至2022年12月31日止年度的核心純利增長約19.5%;公司擁有人應占每股基本盈利約為人民幣1.83元,較去年增加約44.1%。

賽生藥業是專注於腫瘤及重症感染疾病治療領域並擁有產品開發和商業化集成平台的國際生物製藥公司。以創新引領轉型,本集團已建立起了具有差異化優勢的產品組合。秉懷本集團"給生命以希望"的初心,本集團堅持以患者健康為己任,不斷踐行提供國際品質的醫療產品及服務的使命,造福廣大患者。

於2023年,通貨膨脹持續加劇、高利率環境下加息、國際地緣政治局勢日趨緊張,加上覆蘇步伐放緩,均對公司的業務構成巨大挑戰。公司透過多種方式盡力克服上述挑戰,實現了業績的進步。

2023年11月,公司除償還到期債務外,亦主動預付原於2024年11月到期的貸款餘額,提前清理債務。償還及預付債務後,於2023年12月31日,現金及現金等價物以及現金存款(3至12個月或浮動利率)總額約為人民幣22億元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account